XOMA Royalty Completes Acquisition of LAVA Therapeutics, Adding Two Early-Stage Bispecific Antibodies to Portfolio

XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics, acquiring all outstanding common shares for $1.04 in cash per share and a non-transferrable contingent value right. The acquisition adds two early-stage bispecific antibodies to XOMA's portfolio, with potential for significant value creation through future milestones and royalties. The deal reinforces XOMA's "strength in numbers" philosophy and strengthens its position in the biotechnology sector.